News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
AstraZeneca PLC Infant Lung Drug Faces U.S. Delay
December 1, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Nov 28 (Reuters) - AstraZeneca Plc faces a delay in getting a new infant lung drug from its recently acquired MedImmune biotech unit to market in the United States.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Funding
Novo Foundation Pumps $850M Into Denmark, Europe to Bolster Innovation
January 16, 2026
·
2 min read
·
Tristan Manalac
Legal
Former Emergent CEO Hit With Insider Trading Lawsuit
January 16, 2026
·
2 min read
·
Tristan Manalac
Drug pricing
Trump Takes Drug Pricing Fight To Insurers With ‘The Great Healthcare Plan’
January 15, 2026
·
2 min read
·
Annalee Armstrong
FDA
FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
January 15, 2026
·
2 min read
·
Tristan Manalac
